A Study Evaluating PF-03084014 In Patients With Advanced Breast Cancer With Or Without Notch Alterations
NCT ID: NCT02299635
Last Updated: 2019-01-08
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE2
19 participants
INTERVENTIONAL
2015-02-03
2016-01-14
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Biomarker Research Study for PF-03084014 in cHEmoresistant Triple-negative Breast cAncer
NCT02338531
A Single-Arm Phase Ⅱ Study of Fluzoparib Maintenance in Platinum-sensitive Advanced Triple-Negative Breast Cance
NCT07321015
Study of PF-07224826, as a Single Agent or in Combination With Endocrine Therapy in Participants With Breast Cancer and Other Advanced Solid Tumors.
NCT05905341
Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC).
NCT03742349
Tivozanib in Combination With Paclitaxel in Patients With Locally Recurrent or Metastatic Triple Negative Breast Cancer
NCT01745367
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
PF-03084014
PF-03084014 will be administered orally, continuously, twice daily at 150 mg, but the dose can be reduced to 100 mg or 80 mg.
PF-03084014
Tablet, 10 mg, twice a day.
PF-03084014
Tablet, 50 mg, twice a day
PF-03084014
Tablet, 100 mg, twice a day
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
PF-03084014
Tablet, 10 mg, twice a day.
PF-03084014
Tablet, 50 mg, twice a day
PF-03084014
Tablet, 100 mg, twice a day
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Availability of an original diagnostic tumor tissue or the most recent metastatic tumor biopsies (archival biopsy or de novo biopsy) and a peripheral blood sample for Notch receptors genomic profiling
Exclusion Criteria
* Prior treatment with gamma secretase inhibitor or other Notch signaling inhibitor.
18 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Stanford Cancer Institute
Stanford, California, United States
Stanford Hospital and Clinics
Stanford, California, United States
Stanford Women's Cancer Center
Stanford, California, United States
The University of Chicago Medical Center
Chicago, Illinois, United States
University of Chicago Medical Center
Chicago, Illinois, United States
University of Chicago Comprehensive Cancer Center at Silver Cross Hospital
New Lenox, Illinois, United States
Midwestern Regional Medical Center
Zion, Illinois, United States
Brigham and Women's Hospital (BWH)
Boston, Massachusetts, United States
Dana-Farber Cancer Institute (DFCI)
Boston, Massachusetts, United States
Memorial Sloan Kettering Cancer Center Basking Ridge
Basking Ridge, New Jersey, United States
The Valley Hospital - Luckow Pavilion
Paramus, New Jersey, United States
Valley Medical Group
Paramus, New Jersey, United States
Valley Medical Group
Westwood, New Jersey, United States
Memorial Sloan Kettering Cancer Center Commack
Commack, New York, United States
Memorial Sloan Kettering Cancer Center West Harrison
Harrison, New York, United States
Memorial Sloan Kettering Cancer Center
New York, New York, United States
Memorial Sloan Kettering Cancer Center Rockville Centre
Rockville Centre, New York, United States
Memorial Sloan Kettering Cancer Center Sleepy Hollow
Sleepy Hollow, New York, United States
Debreceni Egyetem, Klinikai Kozpont, Onkologiai Intezet
Debrecen, , Hungary
Presidio Ospedaliero Vito Fazzi
Lecce, , Italy
Istitutio Europeo di Oncologia
Milan, , Italy
Vesalius
Krakow, , Poland
Vesalius Poradnia Onkologiczna i Hematologiczna
Krakow, , Poland
Szpital Kliniczny Przemienienia Panskiego, Uniwersutetu Medycznego im. Karola Marcinkowskiego
Poznan, , Poland
Complejo Hospitalario Universitario A Coruna (Hospital Teresa Herrera)
A Coruña, , Spain
Hospital Universitari Vall d'Hebron
Barcelona, , Spain
Hospital Clinic de Barcelona
Barcelona, , Spain
Hospital de la Santa Creu i Sant Pau
Barcelona, , Spain
Instituto Catalan de Oncologia de L'Hospitalet de Llobregat (ICO)
Barcelona, , Spain
Hospital General Universitario Gregorio Maranon
Madrid, , Spain
Hospital Universitario 12 de Octubre
Madrid, , Spain
Hospital Universitario Virgen del Rocio
Seville, , Spain
Hospital Clínico Universitario de Valencia
Valencia, , Spain
Beatson West of Scotland Cancer Centre
Glasgow, Scotland, United Kingdom
Ross Hall Hospital
Glasgow, Scotland, United Kingdom
The Royal Marsden NHS Foundation Trust
London, , United Kingdom
The Royal Marsden NHS Foundation Trust
Surrey, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2014-002286-30
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
A8641020
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.